Aaron,
I wonder if we will see PLE results at all (or if we do, they may be played down).
My sense is PLE is plan B for Clinuvel at this point.
It is all about orhpan indications. Why? See Cerezyme (Gauchers Disease) to understand why. It is based on:
- small number of patients (5,000 in the case of Gauchers)
- extremely high price for the drug (US$200,000 in case of Gauchers / Cerezye)
- high govt subsidies
Clinuvel can make substantial earnings from orphan indications, and can do so very quickly. It is the quickest route to market, and earnings.
PLE is a broad based market strategy. It is incompatible with an orphan approach - gestation period is longer, pricing strategy different (because low govt subsidies for broader application).
My sense is PLE is plan B at this stage. They'll pursue it further down the track once they have they are up and running with their orphan indications.
- Forums
- ASX - By Stock
- CUV
- volume in europe, a precursor?
volume in europe, a precursor?, page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.02 |
Change
-0.280(1.96%) |
Mkt cap ! $702.0M |
Open | High | Low | Value | Volume |
$14.05 | $14.28 | $14.02 | $1.336M | 94.80K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1145 | $14.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.14 | 395 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1145 | 14.020 |
4 | 4836 | 14.010 |
6 | 1801 | 14.000 |
2 | 445 | 13.980 |
2 | 695 | 13.960 |
Price($) | Vol. | No. |
---|---|---|
14.140 | 395 | 1 |
14.160 | 395 | 1 |
14.180 | 395 | 2 |
14.200 | 395 | 1 |
14.310 | 685 | 1 |
Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |